International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 212-217
THE CLINICAL PROGNOSIS OF UNRESECTABLE LUNG ADENOCARCINOMA
METİN ÖZKAN1, ÖZLEM ER1, BÜNYAMİN KAPLAN1, MUSTAFA ALTINBAŞ1, H. ŞENOL COŞKUN1, FEVZİ ALTUNTAŞ1, BÜLENT ESER1, ERAY KARAHACIOĞLU1
Erciyes Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, KAYSERİ
Keywords: adenocarcinoma, unresectable nsclc, prognosis
Lung adenocarcinoma has different epidemiologic and clinical characteristics compared to other nonsmall cell lung cancers. In our study, unresectable 27 lung adenocarcinoma and 80 other nonsmall cell lung cancer patients diagnosed during same period were compared according to clinical behavior. Rate of female and stage IV patients were significantly higher at lung adenocarcinoma group (respectively, p=0.007 and p=0.03). 52% of the adenocarcinoma patients had involvement of mediastinal lymph node and 77% peripherally localized mass. Median progression free survival was 6 months, 1 year progression free survival rate 13% in adenocarcinoma patients. Median overall survival was 8 months, 1 and 2 years survival rate were 24% and 12% respectively. Survival was shorter than other group but this was not statistically significant (respectively, p=0.6 and p=0.14). In conclusion, lung adenocarcinoma is a tumor frequently seen in women, generally peripherally located and potential for distant and mediastinal lymph node metastases is high and has a poor prognosis.
METİN ÖZKAN1, ÖZLEM ER1, BÜNYAMİN KAPLAN1, MUSTAFA ALTINBAŞ1, H. ŞENOL COŞKUN1, FEVZİ ALTUNTAŞ1, BÜLENT ESER1, ERAY KARAHACIOĞLU1
Erciyes Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, KAYSERİ
Keywords: adenocarcinoma, unresectable nsclc, prognosis
Lung adenocarcinoma has different epidemiologic and clinical characteristics compared to other nonsmall cell lung cancers. In our study, unresectable 27 lung adenocarcinoma and 80 other nonsmall cell lung cancer patients diagnosed during same period were compared according to clinical behavior. Rate of female and stage IV patients were significantly higher at lung adenocarcinoma group (respectively, p=0.007 and p=0.03). 52% of the adenocarcinoma patients had involvement of mediastinal lymph node and 77% peripherally localized mass. Median progression free survival was 6 months, 1 year progression free survival rate 13% in adenocarcinoma patients. Median overall survival was 8 months, 1 and 2 years survival rate were 24% and 12% respectively. Survival was shorter than other group but this was not statistically significant (respectively, p=0.6 and p=0.14). In conclusion, lung adenocarcinoma is a tumor frequently seen in women, generally peripherally located and potential for distant and mediastinal lymph node metastases is high and has a poor prognosis.